生命科学资讯
生物技术与制药领域的最新动态
Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
Charles River to close cell therapy CDMO site, lay off 20 staffers
辉瑞每月投入100亿美元押注GLP-1药物，二期b阶段试验显示减肥效果具竞争力。
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
NMD罕见病试验失败，但借次要数据加速项目推进
NMD flunks rare disease trial but flexes secondary data to accelerate program
奎斯特推出多发性骨髓瘤残留病灶血液检测
Quest launches residual disease blood test for multiple myeloma
Mirum如何通过战略并购推动罕见病护理进步
How Mirum is Advancing Rare Disease Care Through Strategic M&A
诺和诺德CagriSema在3期糖尿病研究中优于司美格鲁肽。
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
葛兰素史克归还Wave遗传病RNA编辑技术权利
GSK gives back rights to Wave's genetic disease RNA editor
赛默飞世尔关闭富兰克林工厂，缩减马萨诸塞州员工规模。
Thermo Fisher trims Massachusetts headcount with Franklin site closure
葛兰素史克计划在美英两国裁员多达350名研发人员
GSK plans to lay off up to 350 R&D workers across US, UK
早期投资者Santé Ventures筹集3.3亿美元，布局生物科技、医疗科技与数字健康领域。
Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
罗氏重返RNA领域，以17亿美元收购赛诺基因项目。
Roche's return to RNA continues with $1.7B deal for Sanegene program
Optellum获英国国民医疗服务体系青睐，参与AI肺癌诊断项目。
Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative
中国新索拉以1.35亿美元购得vTv炎症药物剩余权益。
China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug
第一三共暂停内部开发新一代ADC，关键Datroway数据再次延迟公布。
Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again
赛诺菲GCS抑制剂在法布里病三期试验中受挫，却在戈谢病治疗中取得突破。
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
阿斯利康研究发现，22个基因与EB病毒感染后慢性疾病风险相关。
AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection
CRO公司Sygnature Discovery计划裁减60名英国员工
CRO Sygnature Discovery plans to send 60 UK staffers packing